Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhenium (186Re) obisbemeda - Plus Therapeutics

Next Previous
X
Search
Drug Profile

Rhenium (186Re) obisbemeda - Plus Therapeutics

Alternative Names: 186-Rheneium nanoliposome-Plus Therapeutics; 186RNL; Re-186; Rhenium-186 NanoLiposome; RNL™

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plus Therapeutics
  • Class Antineoplastics; Heavy metals; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Meningeal carcinomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • Phase I/II Meningeal carcinomatosis
  • Preclinical Brain cancer; Peritoneal cancer; Squamous cell cancer

Most Recent Events

  • 07 Jun 2024 Efficacy data of CNSide® cerebrospinal fluid cancer diagnostic from the phase I/IIa ReSPECT-LM trial in Meningeal carcinomatosis released by Plus Therapeutics
  • 15 May 2024 Plus Therapeutics anticipates FDA feedback on its ReSPECT-PBC investigational new drug application (IND) for pediatric ependymoma and high-grade glioma, with the goal of obtaining IND approval in the second half of 2024
  • 15 May 2024 Plus Therapeutics plans a Type C meeting with the US FDA for a multi-dose Phase I dose escalation study on June 10, 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top